AbbVie (ABBV) Operating Income (2012 - 2026)

AbbVie has disclosed Operating Income across 15 years of filings, most recently posting $4.0 billion for Q1 2026.

• In Q1 2026, Operating Income rose 6.88% year-over-year to $4.0 billion; the TTM figure through Mar 2026 stood at $15.3 billion (up 52.22% YoY), while the FY2025 annual figure was $15.1 billion, up 64.99% from the prior year.
• Operating Income fell to $4.0 billion in Q1 2026, from $4.5 billion in the prior quarter.
• Over the last five years, Operating Income for ABBV reached as high as $5.5 billion in Q4 2022 and fell as low as -$1.5 billion in Q4 2024.
• The 5-year median for Operating Income is $3.8 billion (2024), against an average of $3.5 billion.
• Annual changes were most pronounced in 2024 — Operating Income tumbled 146.64% — and 2025, when it soared 404.97%.
• A 5-year view of Operating Income shows it stood at $5.5 billion in 2022, then tumbled by 41.93% to $3.2 billion in 2023, then plunged by 146.64% to -$1.5 billion in 2024, then soared by 404.97% to $4.5 billion in 2025, then fell by 12.19% to $4.0 billion in 2026.
• According to Business Quant data, Operating Income over the past three periods registered $4.0 billion, $4.5 billion, and $1.9 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.